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Infection and cancerAbstract Background: Infections remain a part of the natural course of cancer. During the course
of their disease, patients with cancer frequently present with an infection that can ultimately be
fatal. Staphylococcus aureus continues to be a dangerous pathogen for both community-acquired
as well as hospital-associated infections. S. aureus resistant to methicillin was reported soon after
its introduction in October 1960.
Material and methods: We included 40 cancer patients diagnosed with pneumonia, Methicillin
resistance test was checked for all isolates of S. aureus. The selected resistance isolates with positive
phenotypic tests were subjected to molecular screening study using the PCR ampliﬁcation technique
for detection of mec A gene.
Results: 10 samples of patients isolates were positive for staph infection, 7 out of them are
MRSA and conﬁrmed by mec A gene.
Conclusion: In any cancer patients with pneumonia that is proved to be caused by staph aureus
anti MRSA treatment should be initiated empirically.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Since its discovery during the 1880s, Staphylococcus aureus has
emerged as a potentially pathogenic Gram-positive bacterial
species that may cause various infections such as bacteraemia,infective endocarditis, sepsis, toxic shock syndrome, and skin
and soft tissue infections [1].
Since most of these bacteria carry multiple resistance genes
against commonly used antibiotics, they show multiple antibi-
otic resistance patterns thus causing important treatment prob-
lems [2].
Following the introduction of antibiotics, methicillin-
resistant S. aureus (MRSA) has emerged after the acquisition
of a mobile genetic element called the staphylococcal chromo-
somal cassette (SCC) mec, which carries the b-lactamrculosis.
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responsible for methicillin resistance in Staphylococcus [2].
The mec A gene has never been found in methicillin-
susceptible S. aureus (MSSA), while it has been detected in
almost all MRSA isolates [3].
The mec A gene becomes a useful molecular tool for
identiﬁcation of MRSA since molecular techniques (mostly
based on polymerase chain reaction) had been used for the
rapid detection of MRSA [4].
The ability of MRSA to cause a spectrum of human
diseases is due to a combination of host factors and bacterial
virulence factors. Risk factors that have been associated with
MRSA acquisition include age, prolonged hospitalization,
prior antibiotic therapy, severe underlying disease and degree
of disability, surgical procedures, intravascular devices,
mechanical ventilation, impairment of local defence and com-
promised host immunity [5].
Interestingly, cancer patients may have multiple predispos-
ing factors that increase the risk of infection. Chemotherapy,
radiation therapy, surgery, stem cell transplantation, bone
marrow transplantation or steroids in addition to the cancer
itself can suppress the immune system [6].
Therapy should be modiﬁed if there is concern about
resistant organisms that may not be covered by the initial
antimicrobial regimen or if less common aetiologic agents
are suspected [7].
Aim of work
The aim of this work was to study the incidence of staph and
MRSA as a cause of pneumonia in cancer patients.
Material and method
Sputum and blood samples were collected from 40 cancer
patients (25 patients had bronchogenic carcinoma, 5 patients
had leukemias, 3 patients had breast cancer, 4 patients had
urinary bladder carcinoma, 1 patient had pancreatic carci-
noma and 2 patients had HCC) who were admitted to MNF
oncology department who were diagnosed clinically and
radiologically to have pneumonia. Patients with infections
elsewhere in their body were excluded.
Samples were inoculated onto Nutrient, Blood,
MacConkey and mannitol salt agar plates and incubated at
37 C for 24–48 h. The resultant colonies were subjected to
further morphological and biochemical identiﬁcation to iden-
tify different bacterial species according to the standard micro-
biological methods. S. aureus was identiﬁed on the basis of
culture characteristic, morphology and biochemical tests [8].
The isolated Staphylococcus strains were tested for resis-
tance to antimicrobial agents by performing the disc diffusion
method using commercial discs (bioMerieux) according to the
guidelines of the National Clinical Laboratory Standards
Institute [9].
Methicillin resistance test was checked for all isolates of S.
aureus by the oxacillin disc diffusion method of the National
Clinical and Laboratory Standards Institute using 1 lg
oxacillin discs (Hi-Media, India) on Mueller-Hinton agar [10].
The selected resistance isolates with positive phenotypic
tests were subjected to molecular screening study using the
PCR ampliﬁcation technique for detection of mec A gene [11].Results
We included in this study 40 cancer patients who were diag-
nosed to have pneumonia both clinically and radiologically.
Sputum and blood cultures were done to assess incidence of
staph and MRSA as a cause of pneumonia. The selected resis-
tance isolates with positive phenotypic tests were subjected to
molecular screening study using the PCR ampliﬁcation
technique.
We found that the incidence of staph infection within iso-
lates was 25% (10/40 patients) of them, 75% (7/10 patients)
were MRSA and only 30% (3/30 patients) were MSSA,
47.5% (19/40 patients) had other pathogens and 27.5%
(11/40 patients) had no growth.
The other most common pathogens were Escherichia coli
followed by Staphylococcus epidermidis, Klebsiella then
Pseudomonas.
Within the 7 patients with MRSA 5 cases were diagnosed
by blood and sputum culture, 1 case was diagnosed by blood
culture only and 1 case was diagnosed by sputum culture only.
Discussion
Improvements in cancer diagnostic and therapeutic modalities
have resulted in increased ﬂora colonization of cancer patients,
thus increased risk of superimposed infection. This risk can
signiﬁcantly affect prognosis in those patients, especially in
the common context of immunosuppression. Clinicians treat-
ing cancer patients should maintain a high index of suspicion
for infection and orient management towards rapid diagnosis
and appropriate antimicrobial treatment [7].
Eventually, up to 60% of patients with granulocytopenia
develop a lung inﬁltrate at some time reﬂecting pulmonary
infection, associated with a shorter survival time [12].
The major species of pathogenic bacteria isolated from spu-
tum following therapy, S. aureus including MRSA, Klebsiella
pneumoniae, Pseudomonas. aeruginosa, Enterobacte cloacae,
and Acinetobacter calcoaceticus are observed; known to be
frequently involved in hospital-acquired infections [7]. Most
common in our study were staph including MRSA followed
by E. coli then Klebsiella.
In the current study all patients sputum and blood isolates
were cultured for MRSA; the results were conﬁrmed by
oxacillin disc diffusion methods and by detection of the mec
A gene with PCR.
We found that the incidence of staph aureus among
patients was 25%, these results are not going with Ribeiro
et al. [13] surveyed patients seen at the emergency room at a
tertiary hospital in Brazil. Staph infections were found in
93.3% of the patients [13].
Regarding our patients the prevalence of MRSA was
17.5% (7/40 patients) of total number and 70% (7/10 patients)
of staph positive isolates. These results are higher than those of
Ribeiro et al. [13] who found that prevalence of MRSA is 0.7%
among patients in emergency room and they concluded that
MRSA is uncommon among patients visiting the emergency
room; this difference is mostly due to smaller sample size in
our study and speciﬁc selection of immunosuppressed cancer
patients [13].
Our results are higher than that for Falagas et al. [14]
who assessed the prevalence of methicillin-resistance among
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MRSA was lower than 50% in most of the African countries,
although it appears to have risen since 2000 in many African
countries, except for South Africa [14].
Our results are also higher than that of Borg et al. [15]
study, referring to 2003–2005, which was done in nine hospi-
tals as part of the Antibiotic Resistance Surveillance and
Control in the Mediterranean Region (ARMed) project, with
a capture population of 17% of the total country population.
The prevalence of MRSA among S. aureus blood cultures was
52%, exhibiting an increasing trend during the 3-year period of
the study [15].
Regarding Egypt, Ashour and el-Sharif [16], included
cancer patients only, and the prevalence of MRSA among
S. aureus blood cultures was 82%; these results are going with
ours [16].Conclusion
Staph infection represents about 25% of our cases, 75% of
them were MRSA, so it is still unnecessary to start with anti
MRSA treatment, but it is wise to initiate anti MRSA treat-
ment if patient isolates revealed staph infection.Conﬂict of interest
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